Last updated: March 1, 2026
What is NDC 72819-0162?
NDC 72819-0162 corresponds to Ruxolitinib suspension (generic name: Ruxolitinib), developed by Incyte Corporation. It is a JAK1/JAK2 inhibitor indicated for myelofibrosis, polycythemia vera, and other hematologic conditions. The product is structured for pediatric use or specific patient populations requiring an oral suspension form, expanding its administration options.
Market Overview
Therapeutic Landscape
Ruxolitinib competitors include other JAK inhibitors such as Fedratinib (Incyte) and emerging drugs like Momelotinib. The global JAK inhibitor market was valued at approximately $4.8 billion in 2022. A compound annual growth rate (CAGR) of 8% is projected through 2030, driven by increasing indications and new formulations.
Indication Expansion
-
Myelofibrosis: Established use, with annual sales exceeding $1.2 billion for Ruxolitinib (brand Jakafi).
-
Polycythemia Vera: Growing use, with 2022 sales approximate at $680 million.
-
Pediatric and Orphan Markets: The suspension form could open markets for pediatric conditions or cases with swallowing difficulties.
Regulatory Status
-
FDA Approval: Ruxolitinib (tablet form) approved for myelofibrosis, polycythemia vera, and graft-versus-host disease.
-
Priority for Suspension Form: Pending submission or recent approval for pediatric or specific patient groups, potentially in late 2022 or early 2023, subject to regional regulatory timelines.
Market Penetration and Adoption
Current Adoption
-
Existing Use: Ruxolitinib tablets are well established in hematology practices.
-
Suspension Form: Limited data, but expected to penetrate niche markets initially, then expand through physicians’ confidence and pediatric indications.
Factors Influencing Adoption
-
Formulation Acceptance: Ease of use for pediatric or difficult-to-administer populations.
-
Pricing Strategies: Price point comparable to tablets, with potential discounts for orphan or pediatric indications.
-
Regulatory Approvals: Accelerated approval pathways could expedite market entry.
Geographic Focus
-
United States: Largest market, with a strong existing base of hematology treatment.
-
EU and Asia-Pacific: Emerging markets where pediatric formulations are increasingly valued.
Price Projections
Pricing Benchmarks
-
Ruxolitinib Tablets (Jakafi): Wholesale acquisition cost (WAC) is approximately $11,500 per month for an average dose (~20 mg BID).
-
Orphan and Pediatric Premiums: Suspensions tend to command a 10-20% premium due to convenience and patent protections.
Estimated Launch Price for NDC 72819-0162
| Price Factor |
Estimate |
| Monthly Wholesale Price |
$12,000 - $14,500 |
| Annual Revenue Potential |
$144 million - $174 million after first year (assuming 70-80% market penetration in targeted niches) |
Revenue Growth
- Year 1: 10-15% of total Ruxolitinib sales, focusing on niche segments.
- Year 3-5: Market expansion as pediatric and orphan indications gain approval, reaching 20-30% of total Ruxolitinib sales.
Market Risks and Barriers
-
Regulatory Delays: Pediatric approval processes can extend timelines.
-
Market Competition: Launch of alternative JAK inhibitors or biosimilars.
-
Pricing Pressure: Payer negotiations could limit premiums.
Key Takeaways
- NDC 72819-0162’s suspension form positions it for niche pediatric and difficult-to-administer hematology markets.
- The product could generate $144 million to $174 million annually within five years post-launch.
- Market penetration depends on regulatory timelines, physician acceptance, and therapeutic comparability.
- Significant competition and payer pressures remain primary hurdles.
- Expanding indications and geographic growth will influence long-term market share.
FAQs
1. When is NDC 72819-0162 expected to gain regulatory approval?
Approval timelines depend on submission review processes; recent data suggests potential approval in late 2022 or early 2023, primarily in the U.S. and EU.
2. How does the suspension form impact pricing?
Suspensions often command a premium of 10-20% over tablet formulations due to ease of use in specific populations.
3. What are the main competitors for Ruxolitinib suspension?
Main competitors include Fedratinib and upcoming JAK inhibitors like Momelotinib and biosimilars.
4. Which markets offer the highest revenue potential?
The U.S. remains the primary market, followed by the EU and the Asia-Pacific region where pediatric formulations are in demand.
5. What factors could limit the drug's market success?
Regulatory delays, market competition, payer restrictions, and slow physician adoption could restrict growth.
References
[1] IQVIA. (2022). Global Hematology Market Data.
[2] Incyte. (2022). Jakafi (Ruxolitinib) Sales and Market Data.
[3] Grand View Research. (2022). JAK Inhibitors Market Size, Share & Trends.
[4] FDA. (2021). Ruxolitinib New Drug Application Approvals.
[5] EvaluatePharma. (2022). Market Forecast for Hematology Drugs.
